Medical Device Distributors in Switzerland

Switzerland — market overview

Switzerland is approximately €7 billion in annual medical device sales — one of the highest per-capita medical device markets globally, supported by high healthcare spending and a wealthy patient population. The market is structured around 26 cantons, each with significant healthcare autonomy. The breakdown of the EU-Switzerland Mutual Recognition Agreement (MRA) for medical devices in 2021 means manufacturers selling into Switzerland now require a Swiss Authorized Representative (CH-REP) — typically provided by the distributor. This single regulatory complication has reshaped the Swiss distribution landscape, making CH-REP-capable distributors significantly more valuable.

Regulatory framework — and the CH-REP requirement

Medical devices in Switzerland are regulated by Swissmedic. Since May 2021, after the EU-Switzerland MRA lapsed, all medical devices placed on the Swiss market require a Swiss Authorized Representative (CH-REP) — a Swiss-resident legal entity that handles vigilance, registration, and regulatory correspondence on the manufacturer's behalf.

For most non-Swiss manufacturers, the CH-REP role is provided by the distributor. This means a Swiss distribution agreement now bundles CH-REP services with commercial distribution — a meaningful change to the contractual and commercial logic of Swiss market entry.

Hospital procurement and cantonal structure

Swiss hospital procurement is decentralized — most hospitals are cantonally owned and run their own purchasing, sometimes through cantonal purchasing alliances. The five university hospitals (USZ Zurich, CHUV Lausanne, HUG Geneva, Inselspital Bern, Basel) are particularly important for capital equipment and specialty devices.